Santhera seeks speedy FDA review of Duchenne drug vamorolone

[cafead]

via Santhera has completed a rolling application for its Duchenne muscular dystrophy (DMD) therapy vamorolone in the US, setting up a possible approval and launch in the latter half of 2023.

article source